Assessment of Thrombogenicity in Acute Coronary Syndrome

Assessment of Platelet-dependent Thrombosis in Patients With Acute Coronary Syndromes Using an ex Vivo Arterial Injury Model

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00728286

Enrollment

Registered

2008-08-05

Start date

2008-10-31

Completion date

2011-05-31

Last updated

2015-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Type 2 Diabetes Mellitus

Keywords

Type 2 Diabetes Mellitus, Acute Coronary Syndrome, Platelet dependent thrombogenicity

Brief summary

The purpose of this study is to assess platelet dependent thrombogenicity in patients after acute coronary syndrome using an ex vivo arterial injury model.

Detailed description

Abnormal platelet activity seen in patients with Type2 Diabetes Mellitus (T2DM) may be an important contributor to their enhanced cardiovascular risk and higher rates of cardiovascular events following acute coronary syndrome, despite dual antiplatelet therapy with aspirin and clopidogrel. We have earlier demonstrated high thrombogenicity in individuals with T2DM and CAD in the absence of acute ischaemic events, despite therapeutic doses of aspirin.We hypothesise that patients with T2DM will have increased thrombogenicity after acute coronary syndrome despite optimal secondary prevention medication.Measuring ex vivo thrombus area using an arterial injury model simulates plaque rupture and reflects the summative effect of all haemostatic abnormalities. The thrombus area of patients with ACS and T2DM will be compared to the controls without T2DM.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Acute coronary syndrome (WHO criteria) with raised cardiac troponin T * Aged 18-80 years * Stable Acute coronary syndrome * On aspirin and clopidogrel * Willing to participate in the study

Exclusion criteria

* Smoking (current smokers or smokers who quit in the last 6 months preceding recruitment) * Malignancy (any suspected or proven) * Haematological disorders (bleeding disorders) * Pre-menopausal women * Use of corticosteroids/other antithrombotic agents (warfarin) * Chronic liver disease * Unable to consent

Design outcomes

Primary

Measure	Time frame
Thrombus area	Within 10 days after acute coronary syndrome

Secondary

Measure	Time frame
Factors affecting thrombus area	Within ten days after acute coronary syndrome

Countries

United Kingdom

Outcome results